US FDA grants Lupin tentative approval to market generic ulcer drug
A Cloud Migration Plan for Corporations featuring Snowflake®
Investor Activism Campaigns Hit Record High in 2022
Essential IR Insights Newsletter - February 2023
Insight Weekly: US bank margins rise; smartphone shipments drop; coal miners book strong sales
The U.S. FDA granted Lupin Ltd. tentative approval to market its balasalazide disodium tablets, a generic version of Salix Pharmaceutical Inc.'s Giazo.
The drug is meant for the treatment of ulcerative colitis in male patients above the age of 18 years.
